FTE UTILIZATION
85.0%
10.2 / 12 FTE
ACTIVE TRIALS
6
of 8 max
ENROLLMENT RATE
4.8
patients/month
PERFORMANCE SCORE
74
out of 100
MONTHLY OP COST
$85K
22% overhead
ACTIVE TRIALS AT THIS SITE
| PROTOCOL | STATUS | ENROLLMENT | SCREEN FAILURES | FTE |
|---|---|---|---|---|
APEX-301 Advanced Non-Small Cell Lung Cancer | 125 / 180 69% | 18 | 4.5 | |
CARDIO-SHIELD-2 Heart Failure with Reduced Ejection Fraction | 78 / 100 78% | 15 | 2.5 | |
NEURO-PATH-7 Alzheimer's Disease | 68 / 150 45% | 32 | 3.0 | |
ONCO-BRIDGE-9 Advanced Solid Tumors | 26 / 40 65% | 5 | 2.0 |
RECRUITMENT POOLS BY THERAPEUTIC AREA
Oncology
2,080 of 2,500 available
16.8%
+35/mo
Cardiology
2,620 of 3,200 available
18.1%
+45/mo
Neurology
1,480 of 1,800 available
17.8%
+28/mo
PERFORMANCE BY THERAPEUTIC AREA
| THERAPEUTIC AREA | TRIALS | AVG ENROLLMENT | SCREEN FAILURE | DROPOUT |
|---|---|---|---|---|
| Oncology | 8 | 4.2/mo | 32.0% | 15.0% |
| Cardiology | 7 | 5.5/mo | 24.0% | 10.0% |
| Neurology | 3 | 4.1/mo | 27.0% | 11.0% |
SITE INFORMATION
PRINCIPAL INVESTIGATOR
Dr. Sarah Chen, MD, PhD
ADDRESS
2400 Medical Center Drive
Nashville, TN 37203
Nashville, TN 37203
CONTACT
sarah.chen@medpoint.com
(615) 555-0123
CERTIFICATIONS
ACRPCITIGCP
SPECIALTIES
OncologyCardiologyNeurology
CAPACITY BY THERAPEUTIC AREA
Oncology
3 / 4
Cardiology
2 / 3
Neurology
1 / 2
HISTORICAL PERFORMANCE
Trials Completed18
On-Time Rate83%
Budget Accuracy±6.2%
Avg Screen Failure28.0%
Avg Dropout12.0%